-2%
Alphapress (Prazosin) 1 is an alpha-blocker used to treat high blood pressure, reduce heart attack or stroke risk, and manage heart failure and prostate enlargement in men.
Prazosin works by selectively inhibiting postsynaptic alpha-1-adrenoreceptors in vascular smooth muscle, leading to a reduction in total peripheral vascular resistance. In hypertensive individuals, it effectively lowers both systolic and diastolic blood pressure, with a more pronounced effect on diastolic pressure. Notably, abrupt discontinuation of Prazosin does not result in rebound hypertension.
For patients with congestive heart failure (CHF), Prazosin enhances therapeutic outcomes by reducing left ventricular filling pressure and cardiac impedance, while simultaneously improving cardiac output. Unlike some other medications, Prazosin does not induce reflex tachycardia, and in normotensive patients, its effect on blood pressure is minimal.
In individuals with Raynaud’s disease, Prazosin alleviates symptoms by reducing the severity, frequency, and duration of attacks. Additionally, at low doses, it helps improve urinary flow in men with benign prostatic hyperplasia (BPH) by blocking alpha-1 receptors in prostatic and urethral smooth muscle. Clinical research has also indicated that Prazosin therapy does not lead to unfavorable changes in serum lipid profiles.